The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells (pages 1509–1519)
Michael W. N. Deininger, Jorge Cortes, Ron Paquette, Byung Park, Andreas Hochhaus, Michele Baccarani, Richard Stone, Thomas Fischer, Hagop Kantarjian, Dietger Niederwieser, Carlo Gambacorti-Passerini, Charlene So, Insa Gathmann, John M. Goldman, Douglas Smith, Brian J. Druker and François Guilhot
Article first published online: 14 AUG 2007 | DOI: 10.1002/cncr.22936
Clonal cytogenetic abnormalities were detectable in a small proportion of patients with chronic myeloid leukemia who attained a cytogenetic response to imatinib mesylate. Although these abnormalities were similar to those observed in patients with myelodysplastic syndromes (MDS), the incidence of MDS and acute leukemia was low, and outcomes were comparable to the outcomes achieved by patients without such abnormalities.